Skip to main content
. 2014 Dec 12;15:486. doi: 10.1186/1745-6215-15-486

Table 3.

Description of therapies prior to randomization, monitoring during aerosol administration, and outcomes of enrolled infants

Case number Before study aerosol During study aerosol After study aerosol
Surfactant Inotropes Pulmonary vasodilators Ventilator Mode Maximum Temperature (°C) Maximum HR (bpm) Minimum MBP (mmHg) Duration of study aerosol (hours) Was ECMO provided? Time to ECMO (hours) c Neuroimaging at discharge
Control group:
2 Yes Dopamine Milrinone Sildenafil CMV 38.0 177 37 31.1 Yes 1.5 Normal study
4 Yes Dopamine Milrinone HFO 37.5 185 32 72 No Bilateral cephalhematomas, thinning corpus callosum
5 No Dopamine Dobutamine - HFO 38.2 200 47 44.9 Yes 24.2 diffuse abnormality, white matter signal ↑ on T2 weighted MRI
Low-dose IPGE1 group:
3 Yes Dopamine Dobutamine - HFO 33.6 131 46 10.1 Yes 1.5 Normal study
6 No - Milrinone HFO 30.6 118 43 36 Yes Not knowna Unknown
High-dose IPGE1 group:
1 Yes Dopamine Dobutamine - HFO 33.5 142 45 39.5 Yes 1.2 ↑ lactate peak suggestive of HIE
7b Yes Dopamine - CMV 33.7 121 63 34 Yes 4 Grade II IVH and posterior fossa hemorrhage

CMV, conventional mechanical ventilation; HFO, high frequency oscillator.; HIE, hypoxic ischemic encephalopathy; IVH, intraventricular hemorrhage; MRI, magnetic resonance imaging; ↑, increased.

aInfant received ECMO at another institution, time of ECMO not known.

bInfant received low-dose IPGE1 for first 24 hours though randomized to high-dose IPGE1; thereafter switched to low-dose IPGE1.

cTime from stop of study aerosol to initiation of ECMO (hours).